Literature DB >> 7659167

Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs.

J Rhodes1, H Chen, S R Hall, J E Beesley, D C Jenkins, P Collins, B Zheng.   

Abstract

Immune responses are orchestrated by CD4 T lymphocytes, which receive a cognitive signal when clonally distributed receptors are occupied by major histocompatibility complex (MHC) class II-bound peptides on antigen-presenting cells (APCs). The APCs provide costimulatory signals, through macromolecules such as CD80, that regulate outcomes in terms of T-cell activation or anergy. We have studied essential complementary chemical events in the form of Schiff base formation between carbonyls and amines that are constitutively expressed on presenting cell and T-cell surfaces and provide a new target for manipulation of immune responses. Here we show that small Schiff base-forming molecules can substitute for the physiological donor of carbonyl groups and provide a costimulatory signal to CD4 Th-cells through a mechanism that activates clofilium-sensitive K+ and Na+ transport. One such molecule, tucaresol, enhances CD4 Th-cell responses, selectively favouring a Th1-type profile of cytokine production. In vivo tucaresol potently enhances CD4 Th-cell priming and CD8 cytotoxic T-cell priming to viral antigens, and has substantial therapeutic activity in murine models of disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659167     DOI: 10.1038/377071a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

Review 1.  Discovery of immunopotentiatory drugs: current and future strategies.

Authors:  J Rhodes
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Oxidized ATP protection against anthrax lethal toxin.

Authors:  Mahtab Moayeri; Katherine E Wickliffe; Jason F Wiggins; Stephen H Leppla
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers.

Authors:  R W Peck; R Wootton; R Wiggs; G Layton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

5.  Ionotrophic 5-hydroxytryptamine type 3 receptor activates the protein kinase C-dependent phospholipase D pathway in human T-cells.

Authors:  N A Khan; A Hichami
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

Review 6.  Recent advances in antiviral therapy.

Authors:  D Kinchington
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

7.  Lipid tucaresol as an adjuvant for methamphetamine vaccine development.

Authors:  K C Collins; J E Schlosburg; J W Lockner; P T Bremer; B A Ellis; K D Janda
Journal:  Chem Commun (Camb)       Date:  2014-04-21       Impact factor: 6.222

Review 8.  Virus-induced immunopathology.

Authors:  B T Rouse
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

Review 9.  Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential.

Authors:  H Chen; J Rhodes
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

10.  Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug.

Authors:  Jehad Charo; Jan Alvar Lindencrona; Lena-Maria Carlson; Jorma Hinkula; Rolf Kiessling
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.